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Background-—Premature cardiovascular disease limits the duration and quality of life on long-term hemodialysis. The objective of
this study was to deﬁne the frequency of fatal and nonfatal cardiovascular events attributable to atherosclerotic and
nonatherosclerotic mechanisms, risk factors for these events, and the effects of cinacalcet, using adjudicated data collected during
the EValuation of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial.
Methods and Results-—EVOLVE was a randomized, double-blind, placebo-controlled clinical trial that randomized 3883
hemodialysis patients with moderate to severe secondary hyperparathyroidism to cinacalcet or matched placebo for up to
64 months. For this post hoc analysis, the outcome measure was fatal and nonfatal cardiovascular events reﬂecting
atherosclerotic and nonatherosclerotic cardiovascular diseases. During the trial, 1518 patients experienced an adjudicated
cardiovascular event, including 958 attributable to nonatherosclerotic disease. Of 1421 deaths during the trial, 768 (54%) were due
to cardiovascular disease. Sudden death was the most frequent fatal cardiovascular event, accounting for 24.5% of overall
mortality. Combining fatal and nonfatal cardiovascular events, randomization to cinacalcet reduced the rates of sudden death and
heart failure. Patients randomized to cinacalcet experienced fewer nonatherosclerotic cardiovascular events (adjusted relative
hazard 0.84, 95% CI 0.74 to 0.96), while the effect of cinacalcet on atherosclerotic events did not reach statistical signiﬁcance.
Conclusions-—Accepting the limitations of post hoc analysis, any beneﬁts of cinacalcet on cardiovascular disease in the context of
hemodialysis may result from attenuation of nonatherosclerotic processes.
Clinical Trials Registration-—Unique identiﬁer: NCT00345839. URL: ClinicalTrials.gov. ( J Am Heart Assoc. 2014;3:e001363 doi:
10.1161/JAHA.114.001363)
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P atients with end-stage kidney disease (ESKD) receivinghemodialysis are at high risk of death from cardiovas-
cular diseases. In the United States, the mortality rate for
patients receiving dialysis in 2010 was 193/1000 patient-
years, with 42% of deaths attributable to cardiovascular
causes.1 Sudden death accounted for 27% of mortality and
acute myocardial infarction for only 5%. A similar pattern of
cardiovascular mortality has been observed in clinical trials
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that have recruited patients receiving hemodialysis.2,3 Tradi-
tional cardiovascular risk factors do not fully account for the
increased burden of cardiovascular diseases in these patients,
who are exposed to a wide range of physiological and
metabolic stresses that may cause both myocardial and
vascular injury.4 From a pathological perspective, the contri-
bution of atherosclerosis to the increased burden of cardio-
vascular disease is unclear, and other processes such as
myocardial ﬁbrosis and arterial calciﬁcation are likely to be
more important than in nonchronic kidney disease (CKD)
populations.5 This is reﬂected by data from recent clinical
trials exploring the beneﬁts of lipid-lowering interventions in
the hemodialysis population. While statin-based regimens
reduce the risk of events attributable to atherosclerosis, the
impact of lowering low-density lipoprotein (LDL) cholesterol
on cardiovascular events overall is small in diabetic and
nondiabetic patients.3,6,7
Patients with progressive CKD develop disturbances in
biochemical and endocrinological measures of mineral
metabolism, abnormal bone histology, and extraskeletal
calciﬁcation, collectively termed CKD mineral bone disorder.8
Elevated blood levels of calcium, phosphorus, and parathy-
roid hormone (PTH), which characterize this disorder, are
associated with increased cardiovascular deaths in observa-
tional studies.9 The EValuation of Cinacalcet HCl Therapy to
Lower CardioVascular Events (EVOLVE) trial was designed to
establish whether cinacalcet (Sensipar/Mimpara), a calcim-
imetic that lowers PTH, calcium, and phosphorus, would
reduce total mortality and nonfatal cardiovascular events in
hemodialysis patients with moderate to severe secondary
hyperparathyroidism.10 In the trial, 3883 patients from 22
countries with median baseline PTH concentration 693 pg/mL
(10% to 90% range, 363 to 1694 pg/mL) were randomized to
cinacalcet (dose titrated from 30 to 180 mg daily based on
PTH values) or matched placebo for up to 64 months.11 The
primary composite end point was time to death or ﬁrst
nonfatal myocardial infarction, hospitalization for unstable
angina, heart failure, or peripheral vascular event. Cardio-
vascular mortality, stroke, clinical fracture, and parathyroid-
ectomy were prespeciﬁed secondary end points. In an
unadjusted analysis of the EVOLVE trial, cinacalcet did not
signiﬁcantly reduce the risk of death or nonfatal cardiovas-
cular events (relative hazard 0.93, 95% CI 0.85 to 1.02).
Adjusting for baseline characteristics yielded a 12% reduction
in risk of death or nonfatal cardiovascular events (relative
hazard 0.88, 95% CI 0.79 to 0.97) that was nominally
signiﬁcant (P=0.008). Rates of withdrawal from cinacalcet,
often related to gastrointestinal symptoms, were high; this,
along with crossover from placebo to commercially available
cinacalcet, sharply reduced the trial’s power to detect a
statistically signiﬁcant result.11 Another potential explanation
for the lack of deﬁnitive efﬁcacy was that the end point was
a composite of both atherosclerotic and nonatherosclerotic
events.
The aims of this post hoc analysis of the EVOLVE data set
were to better characterize the epidemiology of atheroscle-
rotic and nonatherosclerotic cardiovascular events, deﬁne
associated risk factors, and assess the effects of cinacalcet
on different categories of cardiovascular events. Categoriza-
tion of cardiovascular events was based on the Study of Heart
and Renal Protection (SHARP), in which the LDL cholesterol-
lowering combination therapy under investigation was con-
sidered more likely to reduce rates of atherosclerotic than
nonatherosclerotic cardiovascular events, and the primary
end point of the study was chosen accordingly.6 It was
hypothesized that in EVOLVE, cinacalcet would exert a more
potent effect in reducing events presumed to be of nonath-
erosclerotic etiology, including sudden death and heart failure,
than on events presumed to be of atherosclerotic origin, such
as myocardial infarction, hospitalization for unstable angina,
ischemic stroke, and peripheral vascular disease.
Methods
Study Population and Design
In the EVOLVE trial, 3883 patients with secondary hyperpara-
thyroidism receiving hemodialysis were randomized 1:1 to
receive either cinacalcet or placebo in addition to conven-
tional therapies for CKD–mineral bone disorder (ie, instruc-
tions for dietary phosphorus restriction, phosphate binders,
and vitamin D sterols). The dose of the study drug was titrated
once every 4 weeks during the ﬁrst 20 weeks and every
8 weeks during the subsequent follow-up period (from a
starting dose of 30 mg to a maximum dose of 180 mg daily),
depending on blood levels of PTH and calcium. Dosing of
other medications was left to the discretion of the treating
physicians. Details of the study design,10 characteristics of
patients at baseline,12 and primary trial results11 have
previously been published. The trial was led by an academic
Executive Committee and sponsored by Amgen, Inc. Ethics
committee approval was obtained at all participating sites; all
patients gave informed consent.
Cardiovascular Events
An independent Clinical Events Committee adjudicated all
primary and secondary end points.11 For purposes of our
analyses, cardiovascular events were divided into those
attributable to underlying atherosclerotic disease and those
likely to be a consequence of nonatherosclerotic cardiac or
vascular pathological processes. Atherosclerotic end points
were deﬁned as the ﬁrst occurrence of myocardial infarction,
nonhemorrhagic stroke, hospitalization for unstable angina,
DOI: 10.1161/JAHA.114.001363 Journal of the American Heart Association 2















peripheral vascular event (including nontraumatic amputa-
tion), death associated with a cardiovascular procedure, or
death due to aneurysm dissection or rupture. Nonatheroscle-
rotic end points were deﬁned as the ﬁrst occurrence of heart
failure, hemorrhagic stroke, sudden death, fatal pulmonary
embolism, or death due to other or unknown cardiovascular
cause. Patients could be dually classiﬁed with both an
atherosclerotic and a nonatherosclerotic event.
Statistical Analysis
We used the Pearson v2 test to compare the distribution of
the component clinical events between cinacalcet and
placebo groups for each subset of cardiovascular end points
studied. The effect of cinacalcet was evaluated using the
intention-to-treat principle. Gray’s test was used to compare
the cumulative incidence functions between treatment
groups, accounting for competing events of death from other
causes, loss to follow-up, or consent withdrawal. The marginal
Cox regression method of Wei et al13 was used for unadjusted
and adjusted analyses of time to ﬁrst atherosclerotic and
nonatherosclerotic event, testing the difference between the
relative hazard of the 2 event types. In a similar approach, we
stratiﬁed Cox models based on the Prentice et al14 method for
repeated events by event type to estimate and compare the
relative hazard for repeated atherosclerotic and nonathero-
sclerotic events. Multivariable analyses adjusted for baseline
characteristics, including age, sex, race (white, black, other),
geographic region, history of diabetes mellitus, history of
cardiovascular diseases, and other variables. Based on results
from the primary analysis, a treatment assignment 9 age
interaction term was also included, as the effect of cinacalcet
on the primary composite end point, compared with placebo,
varied by age.
In addition to the composite atherosclerotic and nonath-
erosclerotic end points, we examined individual components
of each composite (eg, myocardial infarction, sudden death,
and heart failure). All inference tests were performed without
adjusting for multiple comparisons. As the effects of
randomization to cinacalcet versus placebo on the primary
composite end point in the primary analysis did not reach
statistical signiﬁcance on an unadjusted log rank test, all
comparisons yielding P<0.05 were deemed nominally signif-
icant. All statistical analyses were conducted using SAS 9.3
(SAS Institute, Inc., Cary, NC).
Results
Descriptive Findings
Cardiovascular disease was the most frequent cause of death
in the EVOLVE population overall (Figure 1), with a distribu-
tion closely reﬂecting the distribution in registry data
collected by the United States Renal Data System.1
Overall, 768 (54%) of 1421 deaths were adjudicated as
being due to cardiovascular causes; of these, 127 (9%) were of
unknown cause but were presumed to be cardiovascular. The
most common mode of cardiovascular death was sudden
death, accounting for 24.5% of all deaths and presumably
reﬂecting cardiac arrhythmias. Of 348 sudden deaths, 45%
were witnessed. Of the nonwitnessed deaths, 36% of patients
had been last seen <24 hours earlier, and 19% were found
dead >24 hours after last being seen. Only 56 (4%) deaths
were attributable to acute myocardial infarction. Annualized
event rates (95% CI) for cardiovascular mortality were 5.1%
(95% CI 4.6% to 5.6%) in patients randomized to cinacalcet
and 5.4% (95% CI 4.9% to 6.0%) in patients randomized to
placebo.
Considering all adjudicated events (fatal and nonfatal)
contributing to the end point of any cardiovascular event, an
adjudicated cardiovascular event occurred in 746 patients
randomized to cinacalcet and in 772 patients randomized to
placebo; 377 and 391 fatal events, respectively, contributed
to the cardiovascular mortality end point (Table 1).
For fatal and nonfatal cardiovascular events of any type,
distribution did not differ among patients randomized to
cinacalcet versus placebo (Table 1). Likewise, distribution
of atherosclerotic and nonatherosclerotic end point
events, whether considering ﬁrst event or all events, was
similar (Table 2). Peripheral vascular events accounted for
the largest fraction of ﬁrst end point events attributed to
atherosclerotic etiology (38.4% and 39.0% in patients
randomized to cinacalcet and placebo, respectively).
Heart failure events accounted for the largest fraction of
ﬁrst nonatherosclerotic end point events (44.3% and














Figure 1. Adjudicated causes of death in the EVOLVE study
population. CV indicates cardiovascular; EVOLVE, EValuation Of
Cinacalcet HCl Therapy to Lower CardioVascular Events.
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Cardiovascular Death and Nonfatal End Points:
Intention-to-Treat Analysis
Table 3 shows the multivariable model analyzing the relative
hazard of fatal and nonfatal cardiovascular events, based on
time to event. In this analysis, randomization to cinacalcet
resulted in a 10% (95% CI 0% to 19%) reduction in the
cardiovascular event rate. Table 4 shows a corresponding
model analyzing the relative hazard of cardiovascular death;
randomization to cinacalcet resulted in a nominally statisti-
cally signiﬁcant 16% (95% CI 2% to 28%) reduction in the
cardiovascular death rate.
Atherosclerotic and Nonatherosclerotic Events
Figure 2A and 2B show unadjusted cumulative incidence
function plots for nonatherosclerotic and atherosclerotic
Table 1. Clinical End Points of Any Cardiovascular Event, Cardiovascular Death, and Composite Cardiovascular End Point by
Clinical Event in Placebo (n=1935) and Cinacalcet Groups (n=1948)
Event Type
Any Cardiovascular Event Cardiovascular Death
Placebo Cinacalcet Placebo Cinacalcet
Myocardial infarction 111 (14.4) 129 (17.3) 29 (7.4) 27 (7.2)
Stroke 79 (10.2) 94 (12.6) 34 (8.7) 48 (12.7)
Heart failure 203 (26.3) 165 (22.1) 34 (8.7) 20 (5.3)
Hospitalization for unstable angina 47 (6.1) 31 (4.2) — —
Peripheral vascular event 152 (19.7) 150 (20.1) — —
Fatal pulmonary embolism 2 (0.3) 5 (0.7) 4 (1.0) 6 (1.6)
Sudden death 115 (14.9) 109 (14.6) 182 (46.5) 166 (44.0)
Death from cardiovascular procedure 4 (0.5) 6 (0.8) 7 (1.8) 15 (4.0)
Other fatal cardiovascular event 15 (1.9) 21 (2.8) 33 (8.4) 36 (9.5)
Unknown cardiovascular death cause 44 (5.7) 36 (4.8) 68 (17.4) 59 (15.6)
Total, n 772 746 391 377
Values are n (%). There were no statistically signiﬁcant differences in the distribution of the component clinical events between the group randomized to placebo and the group randomized
to cinacalcet; v2 P=0.159 and 0.155 for any cardiovascular event end point and cardiovascular death, respectively.
Table 2. Clinical End Points of Atherosclerotic and Nonatherosclerotic Events in Placebo and Cinacalcet Groups
Event Type
Atherosclerotic Event Nonatherosclerotic Event
Placebo Cinacalcet Placebo Cinacalcet
First Event All Events First Event All Events First Event All Events First Event All Events
Myocardial infarction 140 (32.0) 248 (28.5) 150 (35.1) 256 (30.0) — —
Nonhemorrhagic stroke 66 (15.1) 83 (9.5) 63 (14.8) 86 (10.1) — —
Hemorrhagic stroke — — 22 (4.4) 27 (4.1) 34 (7.4) 41 (6.5)
Heart failure — – 236 (47.5) 343 (52.4) 204 (44.3) 327 (52.1)
Hospitalization for unstable angina 54 (12.3) 76 (8.7) 39 (9.1) 64 (7.5) — —
Peripheral vascular event 171 (39.0) 454 (52.1) 164 (38.4) 424 (49.7) — —
Fatal pulmonary embolism — — 3 (0.6) 4 (0.6) 6 (1.3) 6 (1.0)
Sudden death — — 157 (31.6) 182 (27.8) 143 (31.0) 166 (26.5)
Death from cardiovascular procedure 6 (1.4) 7 (0.8) 6 (1.4) 15 (1.8) — —
Other fatal cardiovascular event 1 (0.2) 3 (0.3) 5 (1.2) 8 (0.9) 22 (4.4) 30 (4.6) 26 (5.6) 28 (4.5)
Unknown cardiovascular death cause — — 57 (11.5) 68 (10.4) 48 (10.4) 59 (9.4)
Total, n 438 871 427 853 497 654 461 627
Values are n (%). There were no statistically signiﬁcant differences in the distribution of the component clinical events between the group randomized to placebo and the group randomized
to cinacalcet. v2 P=0.34 and 0.28 for ﬁrst atherosclerotic and nonatherosclerotic events, respectively; 0.204 and 0.475 for all atherosclerotic and nonatherosclerotic events, respectively
(v2 test).
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events accounting for mortality from other causes, loss to
follow-up and consent withdrawal as competing events. The
cumulative incidence of nonatherosclerotic events (Figure 2A)
was marginally lower in the cinacalcet than in the placebo
group (P=0.062).
Several correlates of time to ﬁrst nonatherosclerotic
events were noteworthy (Table 5), including geographic
region (all regions had nominally signiﬁcantly lower rates of
nonatherosclerotic events relative to the United States),
current smoking, and higher diastolic blood pressure at
Table 3. Multivariable Cox Regression Model on Time to the First of Any Cardiovascular Event Using Intent-to-Treat Analysis
Variable Hazard Ratio (95% CI) P Value
Treatment (cinacalcet/placebo) 0.89 (0.80 to 0.99) 0.029
Age 1.03 (1.02 to 1.03) <0.001
Sex (ref, female) 1.18 (1.05 to 1.32) 0.006
Geographical region (ref, United States) 0.002
Russia 0.78 (0.60 to 1.03)
Latin America 0.80 (0.65 to 0.97)
Europe 0.76 (0.66 to 0.87)
Canada 0.74 (0.57 to 0.96)
Australia 0.97 (0.76 to 1.25)
History of coronary artery disease 1.41 (1.22 to 1.63) <0.001
History of cardiac arrhythmia 1.28 (1.11 to 1.49) 0.001
History of diabetes 1.77 (1.57 to 2.01) <0.001
History of heart failure 1.14 (1.00 to 1.28) 0.045
History of peripheral vascular disease 1.40 (1.23 to 1.60) <0.001
History of revascularization 1.19 (1.03 to 1.38) 0.022
History of stroke 1.24 (1.06 to 1.44) 0.007
History of transient ischemic attack 1.16 (0.93 to 1.45) 0.181
Other cardiac disease history
(valvular heart disease, angina)
1.26 (1.11 to 1.42) <0.001
Tobacco use (ref, never) <0.001
Current 1.56 (1.34 to 1.81)
Former 1.13 (1.00 to 1.28)
Type of vascular access (ref, natural fistula) 0.165
Permanent catheter 1.12 (0.96 to 1.32)
Other 1.17 (0.86 to 1.60)
Graft 1.15 (1.00 to 1.33)
Baseline vitamin D use 0.89 (0.79 to 0.99) 0.032
Baseline aspirin use 1.02 (0.91 to 1.15) 0.691
Baseline amiodarone use 0.89 (0.66 to 1.19) 0.427
Baseline proton pump inhibitor use 1.10 (0.98 to 1.23) 0.095
Baseline warfarin use 1.14 (0.94 to 1.38) 0.200
Systolic blood pressure per 10 mm Hg increase 1.04 (1.02 to 1.07) 0.000
Baseline serum HDL per 10 mg/dL increase 1.04 (1.00 to 1.08) 0.033
Baseline albumin, g/dL 0.65 (0.56 to 0.76) <0.001
Dialysis duration, y 1.01 (1.00 to 1.02) 0.128
Variables were selected by backward elimination. The baseline variables corrected serum calcium, hemoglobin, serum phosphorus, and calcium phosphorus product were not included in
the regression model due to lack of statistically signiﬁcant independent association with the end point at a=0.25 in a separate model for each. Baseline use of aspirin, amiodarone, proton
pump inhibitor, or warfarin was added to the ﬁnal model. P=0.257 for interaction of age with treatment. Atrial ﬁbrillation (chronic or paroxysmal) accounted for 67% of reported cardiac
arrhythmias. HDL indicates high-density lipoprotein cholesterol.
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baseline. As hypothesized, there was a 16% (95% CI 4% to
26%) lower hazard of nonatherosclerotic events in patients
randomized to cinacalcet. In contrast, while the hazard of
atherosclerotic events was slightly lower in patients random-
ized to cinacalcet, the difference did not reach statistical
signiﬁcance (12%, 95% CI 1% to 24%) (Table 6). However,
there was no signiﬁcant treatment 9 categorized event
(atherosclerotic versus nonatherosclerotic) type interaction,
either for the time to ﬁrst event or time to repeated events for
atherosclerotic and nonatherosclerotic events (P=0.628 and
0.629 for ﬁrst and repeated events, respectively). In contrast,
in multivariable Cox regression models (intention-to-treat
analysis), the relative hazards of heart failure (relative hazard
0.79, 95% CI 0.66 to 0.96), and sudden death (relative hazard
0.79, 95% CI 0.64 to 0.98) were reduced in patients
randomized to cinacalcet. The number needed to treat for
1 year to prevent 1 sudden death was 145.
Discussion
In this post hoc analysis of the EVOLVE trial data set,
adjudicated fatal and nonfatal cardiovascular events were
examined in detail according to whether the likely underlying
pathological process was presumed to be atherosclerotic or
nonatherosclerotic. These results are inconclusive but sug-
gest a greater relative beneﬁt of cinacalcet on nonathero-
sclerotic cardiovascular events, including sudden death and
heart failure, than on atherosclerotic events. We can specu-
late that the potential cardiovascular beneﬁt of cinacalcet in
the context of hemodialysis may be mediated via nonathero-
sclerotic disease mechanisms, for example, slowing of arterial
calciﬁcation or reducing myocardial calcium accumulation.
Our data suggest that treatment with cinacalcet may reduce
the risk of cardiovascular death. As shown in Table 4, in a Cox
regression model on time to cardiovascular death (by
intention-to-treat analysis), there was a 16% reduction in the
hazard of cardiovascular death for cinacalcet versus placebo
(P=0.023).
The availability of the EVOLVE data set provided the
opportunity to study cardiovascular epidemiology in a well-
deﬁned study population of patients receiving hemodialysis,
randomized in an international controlled trial with adjudi-
cated end points. The results of this analysis deliver a clear
message regarding cardiovascular epidemiology in patients
with moderate to severe secondary hyperthyroidism receiving
hemodialysis, and resolve any lingering doubts regarding the
pre-eminence of sudden death, which is unequivocally the
single most frequent cause of death in this patient population.
We were able to compare the EVOLVE data with United States
Renal Data System registry data with cause of death obtained
from the Death Notiﬁcation (Centers for Medicaid & Medicare
form CMS-2746). The distribution of fatal cardiovascular
events was similar in the EVOLVE population and the United
States Renal Data System registry cohort, although the
EVOLVE population included patients who were younger, had
Table 4. Multivariable Cox Regression on Time to
Cardiovascular Death, Intention-to-Treat Analysis
Variable Hazard Ratio (95% CI) P Value
Treatment (cinacalcet/placebo) 0.84 (0.72 to 0.97) 0.019
Age 1.05 (1.04 to 1.05) <0.001
History of coronary artery disease 1.33 (1.11 to 1.59) 0.002
History of cardiac arrhythmia 1.23 (1.00 to 1.52) 0.051
History of diabetes 1.86 (1.53 to 2.25) <0.001
History of heart failure 1.22 (1.02 to 1.45) 0.029
History of peripheral vascular
disease
1.33 (1.11 to 1.60) 0.002
History of retinopathy 1.15 (0.96 to 1.39) 0.124
History of stroke 1.25 (1.01 to 1.55) 0.044
History of transient ischemic
attack
1.26 (0.93 to 1.71) 0.135
Tobacco use (ref, never) 0.003
Current 1.45 (1.17 to 1.81)
Former 1.06 (0.89 to 1.26)
Type of vascular access
(ref, natural fistula)
0.071
Permanent catheter 1.18 (0.94 to 1.49)
Graft 1.30 (1.05 to 1.59)
Other 1.23 (0.79 to 1.93)
Baseline statin use 0.85 (0.71 to 1.00) 0.053
Baseline aspirin use 1.02 (0.86 to 1.20) 0.858
Baseline amiodarone use 0.92 (0.62 to 1.39) 0.706
Baseline proton pump
inhibitor use
1.14 (0.97 to 1.35) 0.118
Baseline warfarin use 0.95 (0.71 to 1.27) 0.731
Baseline serum phosphorus,
mg/dL
1.14 (1.08 to 1.21) <0.001
Baseline serum albumin, g/dL 0.60 (0.48 to 0.74) <0.001
Baseline serum total
cholesterol, mg/dL
0.99 (0.99 to 1.00) 0.014
Baseline PTH per 100 pg/mL
increase
1.02 (1.01 to 1.03) 0.005
Baseline serum LDL per
10 mg/dL increase
1.06 (1.00 to 1.12) 0.057
Variables were selected by backward elimination. The baseline variables vitamin D
binder use, hemoglobin level, sex, bone-speciﬁc alkaline phosphatase, and high-density
lipoprotein cholesterol were not included initially due to lack of statistically signiﬁcant
independent association with the end point at a=0.25 in a separate model for each.
Baseline use of aspirin, amiodarone, proton pump inhibitor, or warfarin was added to the
ﬁnal model. P=0.047 for interaction of treatment assignment with age. LDL indicates
low-density lipoprotein cholesterol; PTH, parathyroid hormone.
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longer dialysis duration, and in general had more severe
secondary hyperparathyroidism. More importantly, the adju-
dicated EVOLVE data independently validated the enormous
contribution of sudden cardiac death to mortality in patients
with ESKD worldwide.
This pattern of cardiovascular mortality observed in
EVOLVE contrasts with that seen in nonhemodialysis popu-
lations such as those represented in the cholesterol trialists
collaboration meta-analysis of high-risk patients recruited into
randomized controlled trials of statin therapy.15 Among
129 536 participants in 21 such trials, most of whom did
not have CKD, 26% of 15 969 recorded deaths were
attributable to coronary artery disease, and only 8.7% were
sudden in nature (Colin Baigent, BM, MSc, personal commu-
nication, unpublished data, 2013). The discrepancy among the
lipid-lowering trials and EVOLVE may reﬂect the fact that
patients recruited to statin trials have atherosclerosis and are
at high risk of cardiovascular events that complicate this
disease. Cardiovascular events in patients receiving hemod-
ialysis may be largely driven by nonatherosclerotic cardiovas-
cular disease, perhaps resulting from long-term exposure to
hypertension, ﬂuid overload, and disorders of mineral and
endocrine metabolism associated with CKD.5
The SHARP trial examined the impact of LDL cholesterol-
lowering therapy in a population with advanced CKD,
including over 2500 patients receiving hemodialysis. As in
EVOLVE, clinical end points were adjudicated during the
SHARP study, with the primary end point a composite of fatal
and nonfatal cardiovascular events considered by the
Steering Committee to be attributable to atherosclerotic
cardiovascular disease. There was a 17% reduction in such
events among patients allocated to the active intervention
(simvastatin 20 mg plus ezetimibe 10 mg daily) compared
with placebo, but no impact on other cardiovascular disease
events, either fatal or nonfatal. Among the 2509 SHARP
patients receiving hemodialysis at the time of randomization
to study treatment, the beneﬁts of the LDL cholesterol-
lowering regimen appeared to be attenuated, although this
might be attributable to reduced adherence with study
medication, reﬂected in a lesser absolute reduction in blood
A B
C D
Figure 2. Cumulative incidence function plots, intention-to-treat analysis, of (A) nonatherosclerotic events, (B) atherosclerotic events,
(C) heart failure, and (D) sudden death.
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LDL-cholesterol concentrations, limited statistical power in
the ESKD subgroup, or a smaller or absent treatment effect.
A recent meta-analysis of lipid-lowering trials in dialysis-
requiring and nondialysis-requiring CKD patients, including
data from SHARP, concluded that the effects of statin
therapy are attenuated in patients with more advanced CKD
stages.16 It can be inferred from these results that mech-
anisms other than atherosclerosis become more important
drivers of cardiovascular events in advanced CKD and ESKD
and that alternative treatment regimens should be explored
in these patients. In this analysis of the cardiovascular
events in the EVOLVE study, the 16% reduction in nonath-
erosclerotic events among patients randomized to cinacalcet
is congruent with the statistically signiﬁcant 17% reduction in
Table 5. Multivariable Cox Regression Model on Time to First Nonatherosclerotic Event, Intention-to-Treat Analysis
Variable Hazard Ratio (95% CI) P Value
Treatment (cinacalcet/placebo) 0.84 (0.73 to 0.96) 0.009
Age 1.03 (1.03 to 1.04) <0.001
Geographical region (ref, United States) <0.001
Russia 0.57 (0.40 to 0.82)
Latin America 0.76 (0.59 to 0.97)
Europe 0.49 (0.39 to 0.61)
Canada 0.67 (0.48 to 0.93)
Australia 0.69 (0.49 to 0.99)
Race (ref, white) 0.090
Black 0.86 (0.71 to 1.05)
Other 0.81 (0.66 to 0.99)
History of coronary artery disease 1.28 (1.08 to 1.51) 0.004
History of cardiac arrhythmia 1.18 (0.97 to 1.43) 0.100
History of diabetes 1.54 (1.32 to 1.80) <0.001
History of dyslipidemia 0.87 (0.75 to 1.02) 0.079
History of heart failure 1.35 (1.16 to 1.57) 0.000
Other cardiac disease history (valvular heart disease, angina) 1.35 (1.15 to 1.58) 0.000
History of peripheral vascular disease 1.21 (1.03 to 1.44) 0.025
Tobacco use (ref, never) <0.001
Current 1.66 (1.38 to 2.00)
Former 1.14 (0.98 to 1.33)
Type of vascular access (ref, natural fistula) 0.090
Permanent catheter 0.99 (0.80 to 1.22)
Other 1.13 (0.73 to 1.74)
Graft 1.25 (1.04 to 1.49)
Baseline aspirin use 0.98 (0.85 to 1.14) 0.809
Baseline amiodarone use 1.10 (0.75 to 1.62) 0.617
Baseline proton pump inhibitor use 1.08 (0.94 to 1.25) 0.285
Baseline warfarin use 0.97 (0.75 to 1.25) 0.794
Baseline serum cholesterol per 10 mg/dL increase 0.98 (0.97 to 1.00) 0.058
Baseline serum HDL per 10 mg/dL increase 1.04 (0.99 to 1.08) 0.112
Baseline serum albumin, g/dL 0.68 (0.56 to 0.82) <0.001
Diastolic blood pressure per 10 mm Hg increase 1.09 (1.04 to 1.15) 0.001
Variables were selected by backward elimination. The baseline variables sex, hemoglobin, corrected serum calcium, serum phosphorus, and calcium phosphorus product were not included
in the regression model due to lack of statistically signiﬁcant independent association with the end point at a=0.25 in a separate model for each. Baseline use of aspirin, amiodarone,
proton pump inhibitor, or warfarin was added to the ﬁnal model. P=0.359 for interaction of treatment with age. HDL indicates high-density lipoprotein.
DOI: 10.1161/JAHA.114.001363 Journal of the American Heart Association 8















atherosclerotic events attributable to the LDL cholesterol-
lowering regimen in the SHARP study.
Observational data have highlighted important associations
among abnormalities of bone and mineral metabolism and
adverse outcomes. Several studies in patients with ESKD have
linked very low and very high PTH concentrations with
mortality, sudden death, and cardiovascular events17,18;
experimental studies have identiﬁed plausible biological
mechanisms linking CKD-associated mineral and endocrine
abnormalities to both arterial19 and left ventricular disease.20
Further evidence for the role of secondary hyperparathyroidism
in the pathogenesis of CKD-related cardiovascular disease can
be derived from clinical and experimental studies. Both primary
and secondary hyperparathyroidism are associated with left
ventricular hypertrophy,21,22 and in the context of hemodial-
ysis, parathyroidectomy improves left ventricular function.23
Cardiovascular beneﬁts of cinacalcet could also result from
a reduction in calciﬁcation of the cardiovascular system. A
Randomized Study to Evaluate the Effects of Cinacalcet plus
Low-Dose Vitamin D on Vascular Calciﬁcation in Subjects with
Chronic Kidney Disease Receiving Hemodialysis (ADVANCE)
was designed to test this hypothesis in a clinical setting.
Inclusion and exclusion criteria and the dose titration schedule
were similar to EVOLVE; 360 hemodialysis patients were
randomized to cinacalcet or placebo with baseline and follow-
up computed tomography scans to assess coronary artery and
aortic calciﬁcation. The ADVANCE trial results did not reach
conventional levels of statistical signiﬁcance for the primary
outcome (change in Agatston coronary artery calciﬁcation
score), but the change in volume score (a secondary outcome)
was nominally signiﬁcant and the results are consistent with a
modest effect of cinacalcet on slowing progression of
cardiovascular calciﬁcation.24 The physiological conse-
quences of arterial calciﬁcation in the context of CKD may
include arterial stiffening,25 which may in turn increase left
ventricular afterload and hypertrophy and failure. Thus, a
reduction in arterial calciﬁcation and stiffening in response to
cinacalcet therapy might plausibly reduce cardiovascular
events associated with left ventricular disease, such as heart
failure and sudden death. Another potential beneﬁt of
cinacalcet might be a reduction in serum levels of ﬁbroblast
growth factor-23, a phosphatonin that has been implicated in
the development of left ventricular hypertrophy in the context
of CKD.20 A modest reduction in ﬁbroblast growth factor-23
has been suggested in a recent open-label single-arm trial of
cinacalcet involving 55 participants receiving hemodialysis,26
along with the expected reduction in blood PTH.
As shown in EVOLVE, sudden death is an important factor
limiting the lifespan of hemodialysis patients. Risk factors for
sudden death included higher baseline serum phosphorus and
lower serum albumin concentrations. Further studies are
required to deﬁne risk factors for sudden cardiac death and
its relationship to the dialysis cycle and to better target
methods to detect at-risk patients and therapies (such as
deﬁbrillators) that might affect this end point.27,28
In determining the effects of cinacalcet on atherosclerotic
and nonatherosclerotic events, strengths of these analyses
include the randomized design; a large sample size; diversity
in age, sex, race/ethnicity, and clinical features of ESKD; the
breadth of comorbidity and laboratory data available at study
entry; and the availability of carefully adjudicated end points.
There are several important limitations. While several deter-
minants of atherosclerotic and nonatherosclerotic events
unrelated to treatment were identiﬁed, we did not include
Table 6. Multivariable Cox Regression Model on Time to First
Atherosclerotic Event Using Intention-to-Treat Analysis
Variable Hazard Ratio (95% CI) P Value
Treatment (cinacalcet/placebo) 0.88 (0.76 to 1.01) 0.066
Age 1.03 (1.02 to 1.03) <0.001
Sex (ref, female) 1.17 (1.01 to 1.36) 0.039
History of transient ischemic attack 1.43 (1.10 to 1.87) 0.008
History of coronary artery disease 1.58 (1.30 to 1.91) <0.001
History of cardiac arrhythmia 1.36 (1.12 to 1.67) 0.002
History of diabetes 1.76 (1.47 to 2.10) <0.001
History of bone fracture 1.11 (0.94 to 1.31) 0.224
History of peripheral
vascular disease
1.69 (1.43 to 2.00) <0.001
History of retinopathy 1.27 (1.07 to 1.51) 0.007
History of revascularization 1.37 (1.12 to 1.67) 0.002
Tobacco use (ref, never) <0.001
Current 1.50 (1.23 to 1.82)
Former 1.14 (0.97 to 1.34)
Baseline aspirin use 1.05 (0.90 to 1.23) 0.543
Baseline amiodarone use 0.79 (0.53 to 1.19) 0.260
Baseline proton pump inhibitor use 1.08 (0.93 to 1.25) 0.333
Baseline warfarin use 1.03 (0.78 to 1.34) 0.854
Bone-specific alkaline
phosphatase, ng/L
0.99 (0.98 to 1.01) 0.222
N-telopeptide (log-transformed) 1.09 (0.98 to 1.21) 0.131
Baseline serum albumin, g/dL 0.66 (0.54 to 0.82) <0.001
Systolic blood pressure per
10 mm Hg increase
1.06 (1.02 to 1.09) 0.001
Variables were selected by backward elimination. The baseline variables calcium-
containing phosphate binder use, corrected serum calcium, cholesterol, serum
phosphorus, calcium phosphorus product, high-density lipoprotein and low-density
lipoprotein cholesterol were not included in the regression model due to lack of
statistically signiﬁcant independent association with the end point at a=0.25 in a
separate model for each. Baseline use of aspirin, amiodarone, proton pump inhibitor, or
warfarin was added to the ﬁnal model. P=0.11 for interaction of treatment with age. P
value for difference between treatment assignment effect on atherosclerotic and
nonatherosclerotic end points=0.622.
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time-varying covariates (eg, blood pressure, laboratory study
results), so misclassiﬁcation might have occurred, biasing the
relations among these variables and cardiovascular events
toward the null. Importantly, our estimate of the cinacalcet
treatment effect is strongly inﬂuenced by adherence and
crossover, and the confounding effects of parathyroidectomy.
These factors in aggregate are likely to sharply attenuate the
observed treatment effect. Perhaps most importantly, while
the distinction of atherosclerotic and nonatherosclerotic is
contextually of interest, the 2 obviously overlap. For example,
some peripheral vascular events, including nontraumatic
amputation, result primarily from arteriosclerosis of smaller
caliber vessels, not atherosclerosis of larger caliber vessels.
Although peripheral arterial disease is conventionally consid-
ered to be predominantly attributable to atherosclerotic
mechanisms (eg, as illustrated by the SHARP trial design),
we would suggest that in patients with ESKD, much of
peripheral vascular disease could be related to severe
obliterative arteriosclerosis with medial vascular calciﬁcation,
as seen with calciﬁc uremic arteriolopathy (calciphylaxis).
Conversely, while many cases of heart failure result from
impaired ventricular relaxation related to hypertension and
vascular stiffness, some may reﬂect an anginal equivalent,
without diagnosed unstable angina or myocardial infarction
(or even chest pain). With respect to myocardial infarction, we
did not distinguish between type 1 (eg, plaque rupture) and
type 2 (eg, demand ischemia).
In summary, we highlight the contribution of presumed
nonatherosclerotic mechanisms to cardiovascular disease in
the hemodialysis population and the importance of sudden
death as a preventable cause of premature mortality.
Although the EVOLVE trial did not show an unequivocal
beneﬁt of cinacalcet on the primary composite end point, the
analyses presented herein suggest the possibility of a modest
(but clinically meaningful) beneﬁt in cardiovascular end points,
particularly cardiovascular death, sudden death, and heart
failure. Recognizing the exceptionally high risk of death and
cardiovascular disease in ESKD, the complex role of second-
ary hyperparathyroidism in dystrophic calciﬁcation, and the
capacity of cinacalcet to effectively control parathyroid
hormone levels, results from EVOLVE can (and should) inform
clinical practice.
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